Related to FDA’s Appeal for Budget Hike Will Have to Succumb to Budget Reality

• FDA Clears Subcutaneous Velcade for All Approved Indications
  
• FDA Gets Top Grades for Bringing New Drugs to Market from Most GEN Voters
  
• President Obama Restates Case for Basic Research in State of the Union Address
  
• NIH Won’t Survive FY 2013 Without Budget Reduction, GEN Poll Predicts
  
• FDA Clears Leo’s Picato Gel for 2–3 Day Treatment of Actinic Keratosis
  
• FDA Clears Roche’s Erivedge for Treating Advanced Basal Cell Carcinoma
  
• Pfizer’s Inlyta Approved in U.S. as Therapy for Advanced Renal Cell Carcinoma
  
• FDA Email-Monitoring Policies at Issue in Lawsuit Filed Against Agency
  
• FDA Sanctions Vertex’ Kalydeco for Treating Cystic Fibrosis Caused by G551D Mutations
  
• FDA Approves Label Change Recommending Three Years of Novartis' Glivec After GIST Surgery
  
• Roche’s Cobas Test for Chlamydia and Gonorrhea Granted 510(k) Clearance in U.S.
  
• FDA Okays Shire's ADHD Drug Vyvanse for Maintenance Therapy in Adults
  
• FDA Issues Draft Guidance for Getting Biosimilars Approved
  
• FDA Taps MolecularHealth for Its Mechanism-Based Drug Safety Assessment Tool
  
• FDA Clears Gen-Probe’s PCA3 Urine Assay for Predicting Need for Repeat Prostate Biopsies
  
• BioSante, Teva Win FDA Nod for Male Hypogonadism Therapy
  
• Uncertainty Surrounds Proposed 2013 Budget for FDA and CDC, GEN Poll Suggests
  
• FDA Clears MedImmune’s FluMist Quadrivalent Flu Vaccine
  
• Poll Respondents Undecided About Helpfulness of President's Proposed Budgets for NIH, NSF
  
• FDA Clears Discovery Laboratories’ Drug for Respiratory Distress Syndrome in Infants